Oric Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39269 | 3.1 | 4/28/20 |
| 3.2 | Amended and Restated Bylaws of the Registrant | 8-K | 001-39269 | 3.1 | 3/24/23 |
| 4.1 | Specimen Common Stock Certificate of the Registrant | S-1/A | 333-236792 | 4.2 | 4/20/20 |
| 4.2 | Description of the Registrant’s securities | 10-K | 001-39269 | 4.3 | 3/21/22 |
| 4.3 | Form of Pre-Funded Warrant | 8-K | 001-39269 | 4.1 | 5/28/25 |
| 10.1 | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers | S-1 | 333-236792 | 10.1 | 2/28/20 |
| 10.2+ | 2014 Equity Incentive Plan, as amended, and forms of agreement thereunder | S-1 | 333-236792 | 10.2 | 2/28/20 |
| 10.3+ | 2020 Equity Incentive Plan and forms of agreements thereunder | S-1/A | 333-236792 | 10.3 | 4/20/20 |
| 10.4+ | 2020 Employee Stock Purchase Plan and forms of agreements thereunder | 10-Q | 001-39269 | 10.2 | 11/8/21 |
| 10.5+ | Employment Letter between the Registrant and Jacob M. Chacko, M.D. | S-1 | 333-236792 | 10.5 | 2/28/20 |
| 10.6+ | Employment Letter between the Registrant and Pratik Multani, M.D. | S-1 | 333-236792 | 10.6 | 2/28/20 |
| 10.7+ | Employment Letter between the Registrant and Dominic Piscitelli | S-1 | 333-236792 | 10.7 | 2/28/20 |
| 10.8+ | Executive Incentive Compensation Plan | S-1 | 333-236792 | 10.8 | 2/28/20 |
| 10.9+ | Change in Control and Severance Policy | S-1 | 333-236792 | 10.9 | 2/28/20 |
| 10.10+ | Amended and Restated Outside Director Compensation Policy | Filed herewith | |||
| 10.11 | Lease between the Registrant and Britannia Pointe Grand Limited Partnership, dated June 5, 2015 | S-1 | 333-236792 | 10.11 | 2/28/20 |
| 10.12 | First Amendment to Lease between the Registrant and Britannia Pointe Grand Limited Partnership, dated August 12, 2021 | 8-K | 001-39269 | 10.1 | 8/16/21 |
| 10.13+ | Amended and Restated 2022 Inducement Equity Incentive Plan, and form agreements thereunder | 8-K | 001-39269 | 10.1 | 3/14/25 |
| 10.14# | License Agreement between the Registrant and Mirati Therapeutics, Inc., dated as of August 3, 2020. | 10-Q | 001-39269 | 10.2 | 5/9/22 |
| 10.15# | License and Collaboration Agreement between the Registrant and Voronoi, Inc., dated as of October 19, 2020. | 10-Q | 001-39269 | 10.3 | 5/9/22 |
| 10.16 | Amendment No.1 to the License and Collaboration Agreement between the Registrant and Voronoi Inc., effective March 20, 2024 | 10-Q | 001-39269 | 10.1 | 5/6/24 |
| 10.17 | Open Market Sales AgreementSM by and between the Registrant and Jefferies LLC, dated May 6, 2021 | 8-K | 001-39269 | 1.1 | 5/6/21 |
| 10.18 | Securities Purchase Agreement, dated June 24, 2023 | 8-K | 001-39269 | 10.1 | 6/27/23 |
| 10.19 | Stock Purchase Agreement, dated January 20, 2024 | 8-K | 001-39269 | 10.1 | 1/22/24 |
| 10.20 | Securities Purchase Agreement, dated May 23, 2025 | 8-K | 001-39269 | 10.1 | 5/28/25 |
| 19.1 | Insider Trading Policy, as amended | 10-K | 001-39269 | 19.1 | 2/18/25 |
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed herewith | |||
| 24.1 | Power of Attorney (included on the signature page to this Annual Report on Form 10-K) | Filed herewith | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith | |||
| 97.1+ | Compensation Recovery Policy | 10-K | 001-39269 | 97.1 | 3/11/24 |
| 101.INS | Inline XBRL Instance Document | Furnished herewith | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Document | Furnished herewith | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | Furnished herewith | |||
| + | Indicates management contract or compensatory plan. |
|---|---|
| # | Portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (1) the omitted information is not material and (2) the omitted information would likely cause competitive harm to the registrant if publicly disclosed. |
| * | The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of ORIC Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.